ClinicalTrials.gg
CompletedNCT00964795Updated Mar 23, 2015Results posted

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

A Phase 3 interventional study of Intravitreal Aflibercept Injection 2mg in Neovascular Age-related Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 124 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-03-23.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
323
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
13th of 66
323 · median 55
Started
2009
the only one that year
Phase 3
18 of 66
1 open now
Registered
6th of 66
by date
Lead sponsor
10 of 66
Regeneron Pharmaceuticals

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 13th largest by enrollment, is the only one that started in 2009, is one of 18 in phase 3, and was the 6th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.

Read the detailed description

The dose evaluated in this study, Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg, will be the higher of the 2 dose strengths evaluated in parent study VGFT-OD-0605 (NCT00509795) and is the dose level administered in study VGFT-OD-0702 (NCT00527423), a long-term open-label extension study. For these reasons, this dose has been selected for this extension study.

Participants will be seen in the clinic for quarterly visits starting with day 1 to assess safety. Study drug will be administered on an as-needed basis at the discretion of the investigator with a minimum allowed interval of every 4 weeks and a maximum allowed interval of every 12 weeks. This study will assess the frequency that re-treatment is needed and the effect of continued Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) treatment on BCVA.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • Eyes
  • Neovascular
  • Macular Degeneration
  • Retina
  • AMD
  • VEGF Trap-Eye
  • Best Corrected Visual Acuity
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participation in Study VGFT-OD-0605 through week 96.
  • In the opinion of the investigator, the study eye has neovascular AMD and may continue to require treatment.

Exclusion criteria

Exclusion Criteria:

  • Presence of any condition that would jeopardize the patient's participation in this study.
  • Females who are pregnant, breastfeeding, or of , unwilling to practice adequate throughout the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
323 participants (actual)

Study arms

  • Experimental
    Open-label Intravitreal Aflibercept Injection

    Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.

    Drug: Intravitreal Aflibercept Injection 2mg

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD

    The primary endpoint in the study is the safety and tolerability of Intravitreal Aflibercept Injection in patients with neovascular AMD (Age-related Macular Degeneration) from day 1 through the end of treatment visit (week 180) based on the number of participants who experienced any treatment-emergent adverse event (TEAE). Treatment-emergent adverse events were categorized according to Ocular TEAEs in the study eye, Ocular TEAEs in the fellow eye, and Non-Ocular TEAEs

    Time frame: Baseline (day 1) through end of treatment (Week 180)

Secondary outcomes

  1. Change in BCVA Letter Score (mLOCF)

    The secondary endpoint in the study is the change in BCVA letter score from baseline through Week 116. (mLOCF: The last non-missing observation prior to the missing visit was carried forward to impute the missing data; no imputation after last visit; no baseline value carried forward).

    Time frame: Baseline through Week 116

Other outcomes

  1. Summary of Treatment Duration (Weeks)

    Treatment Duration = (last dose date - first dose date + 28)/7

    Time frame: Baseline through end of treatment (Week 180)

  2. Summary of Study Duration (Weeks)

    Study Duration = (last visit/ discontinuation date - first dose date + 28)/7

    Time frame: Baseline through end of treatment (Week 180)

07

Results

Posted Mar 23, 2015

Participant flow

After informed consent was obtained, the 323 participants who completed the parent study, VGFT-OD-0605 (NCT00509795), and met the protocol eligibility criteria, were enrolled at 71 clinical sites in the US \& Canada. The first visit occurred concurrently with the last visit in the parent study. The last participant entered this study on 18-May-2011.

Participant flow — Overall Study
MilestoneOpen-label Intravitreal Aflibercept Injection
Started323
Number of participants treated320
Completed16
Not completed307
Withdrew: Withdrawal by subject79
Withdrew: Adverse event12
Withdrew: Death14
Withdrew: Lost to follow-up7
Withdrew: Termination of study by sponsor169
Withdrew: Unwilling to sign icf for amendment 43
Withdrew: Other23

Outcome measures

PrimarySafety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD

The primary endpoint in the study is the safety and tolerability of Intravitreal Aflibercept Injection in patients with neovascular AMD (Age-related Macular Degeneration) from day 1 through the end of treatment visit (week 180) based on the number of participants who experienced any treatment-emergent adverse event (TEAE). Treatment-emergent adverse events were categorized according to Ocular TEAEs in the study eye, Ocular TEAEs in the fellow eye, and Non-Ocular TEAEs

Time frame:
Baseline (day 1) through end of treatment (Week 180)
Reported as:
Number · participants
Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD
participantsOpen-label Intravitreal Aflibercept Injection
Number of participants with any TEAE290
Any ocular TEAE239
Any ocular TEAE: Study eye204
Any ocular TEAE: Fellow eye169
Any non-ocular TEAE232
Any serious TEAE105
Discontinuation of study due to AE12
Any Death due to TEAE17
SecondaryChange in BCVA Letter Score (mLOCF)

The secondary endpoint in the study is the change in BCVA letter score from baseline through Week 116. (mLOCF: The last non-missing observation prior to the missing visit was carried forward to impute the missing data; no imputation after last visit; no baseline value carried forward).

Time frame:
Baseline through Week 116
Reported as:
Mean · letters correctly read
Change in BCVA Letter Score (mLOCF)
letters correctly readOpen-label Intravitreal Aflibercept Injection
Change in BCVA Letter Score (mLOCF)-2.7 ± 12.50
Other pre-specifiedSummary of Treatment Duration (Weeks)

Treatment Duration = (last dose date - first dose date + 28)/7

Time frame:
Baseline through end of treatment (Week 180)
Reported as:
Mean · weeks
Summary of Treatment Duration (Weeks)
weeksOpen-label Intravitreal Aflibercept Injection
Summary of Treatment Duration (Weeks)110.4 ± 42.16
Other pre-specifiedSummary of Study Duration (Weeks)

Study Duration = (last visit/ discontinuation date - first dose date + 28)/7

Time frame:
Baseline through end of treatment (Week 180)
Reported as:
Mean · weeks
Summary of Study Duration (Weeks)
weeksOpen-label Intravitreal Aflibercept Injection
Summary of Study Duration (Weeks)116.9 ± 44.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Intravitreal Aflibercept Injection—105/323 (32.5%)102/323 (31.6%)
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventOpen-label Intravitreal Aflibercept Injection
FallInjury, poisoning and procedural complications16/323
Atrial FibrillationCardiac disorders12/323
SyncopeNervous system disorders8/323
Acute Myocardial InfarctionCardiac disorders5/323
PneumoniaInfections and infestations5/323
Urinary Tract InfectionInfections and infestations5/323
Cerebrovascular AccidentNervous system disorders5/323
Cardiac ArrestCardiac disorders4/323
Coronary Artery DiseaseCardiac disorders4/323
Myocardial InfarctionCardiac disorders4/323
Most frequent other events
Showing 10 of 14
Most frequent other events
EventOpen-label Intravitreal Aflibercept Injection
Retinal HaemorrhageEye disorders39/323
Retinal HaemorrhageEye disorders34/323
Age-Related Macular DegenerationEye disorders30/323
Conjunctival HaemorrhageEye disorders30/323
HypertensionVascular disorders29/323
FallInjury, poisoning and procedural complications23/323
NauseaGastrointestinal disorders22/323
NasopharyngitisInfections and infestations22/323
Upper Respiratory Tract InfectionInfections and infestations20/323
BronchitisInfections and infestations19/323

Baseline characteristics

Randomized participants included all participants who were enrolled in the study. The data were used to analyze the safety and efficacy parameters to characterize the long-term effect of Intravitreal Aflibercept Injection treatment. The average study duration for all enrolled participants was 116.9 weeks.

Age, Continuous
Age, Continuous(years)Open-label Intravitreal Aflibercept Injection
Mean79 ± 7.83
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Intravitreal Aflibercept Injection
Female196
Male127
08

Study locations

124 sites
  • Birmingham (2 locations), Alabama, United States
  • Phoenix (2 locations), Arizona, United States
  • Tucson (2 locations), Arizona, United States
  • Arcadia, California, United States
  • Beverly Hills, California, United States
  • Campbell, California, United States
  • Fresno, California, United States
  • Fullerton, California, United States
  • La Jolla, California, United States
  • Loma Linda, California, United States
  • Mountain View, California, United States
  • Oakland, California, United States
  • Orange, California, United States
  • Palm Desert, California, United States
  • Sacramento, California, United States
  • San Mateo, California, United States
  • Santa Ana, California, United States
  • Torrance, California, United States
  • Westlake Village, California, United States
  • Yorba Linda, California, United States
  • Colorado Springs, Colorado, United States
  • Denver (2 Locations), Colorado, United States
  • Bridgeport, Connecticut, United States
  • New Haven, Connecticut, United States
  • New London, Connecticut, United States
  • Altamonte Springs, Florida, United States
  • Boynton Beach, Florida, United States
  • Fort Myers (2 locations), Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Orlando (2 locations), Florida, United States
  • Oscala, Florida, United States
  • Palm Beach Gardens, Florida, United States
  • Pensacola, Florida, United States
  • Stuart, Florida, United States
  • Tampa, Florida, United States
  • Winter Haven, Florida, United States
  • Augusta, Georgia, United States
  • Aiea, Hawaii, United States
  • Glenview, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Indianapolis, Indiana, United States
  • New Albany, Indiana, United States
  • Iowa City, Iowa, United States
  • Wichita, Kansas, United States
  • Louisville, Kentucky, United States
  • New Orleans, Louisiana, United States
  • Bangor, Maine, United States
  • Portland, Maine, United States
  • Baltimore (3 Locations), Maryland, United States
  • Chevy Chase, Maryland, United States
  • Hagerstown, Maryland, United States
  • Boston (2 Locations), Massachusetts, United States
  • Peabody, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Battle Creek, Michigan, United States
  • Grand Rapids, Michigan, United States
  • Jackson, Michigan, United States
  • Southfield, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Rochester, Minnesota, United States
  • Florissant, Missouri, United States
  • Kansas City, Missouri, United States
  • Springfield, Missouri, United States
  • St. Louis, Missouri, United States
  • Missoula, Montana, United States
  • Lincoln, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Portsmouth, New Hampshire, United States
  • Lawrenceville, New Jersey, United States
  • Northfield, New Jersey, United States
  • Toms River, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • Brooklyn, New York, United States
  • Lynbrook, New York, United States
  • New York (6 locations), New York, United States
  • Rochester (2 locations), New York, United States
  • Slingerlands, New York, United States
  • Syracuse, New York, United States
  • Asheville, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Ashland, Oregon, United States
  • Portland (3 Locations), Oregon, United States
  • Salem, Oregon, United States
  • Kingston, Pennsylvania, United States
  • Philadelphia (3 locations), Pennsylvania, United States
  • Pittsburgh (2 locations), Pennsylvania, United States
  • West Mifflin, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Greenville, South Carolina, United States
  • West Columbia, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Nashville, Tennessee, United States
  • Austin (3 Locations), Texas, United States

Showing the first 100 of 124 sites across 2 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2009
First posted
Aug 25, 2009
Start
Dec 2009
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Mar 23, 2015
Last update
Mar 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00964795
Collaborators
Bayer
Responsible party
Sponsor
First posted
Aug 25, 2009
Start date
Dec 2009
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Mar 23, 2015
Last update
Mar 23, 2015

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion